Analytical report estimates a $24 million to $86 million fair-market-value range and a conditional $70 million to $185 million strategic-value range
HUNTINGTON BEACH, Calif., August 27, 2026 — Lionheart Health, Inc. and Leonhardt Ventures LLC today announced the completion of an analytical valuation report covering their intellectual-property portfolio in bioelectric regenerative medicine, controlled protein expression, longevity, neuroregeneration, tissue and organ repair, Klotho modulation, Klotho-expressing stem cells and related neuro-electrical technologies.
The report concludes that the most supportable current indicative fair-market-value range for the included portfolio is $24 million to $86 million, with a probability-weighted central indication of approximately $47 million.
For a strategic acquirer or field-exclusive licensee capable of accelerating clinical development, regulatory clearance, manufacturing and distribution, the report identifies a conditional strategic-value range of approximately $70 million to $185 million, with a central strategic indication of approximately $115 million.
“This report provides an important analytical framework for understanding the potential value of the regenerative-medicine intellectual property that Lionheart Health and Leonhardt Ventures have developed and assembled over many years,” said Howard J. Leonhardt, Founder and Executive Chairman of Lionheart Health and Founder of Leonhardt Ventures. “We believe the greatest potential value comes from combining programmable bioelectric signaling with Klotho modulation, regenerative cells, exosomes, peptides, nutrient hydrogels and indication-specific treatment protocols.”
Portfolio valuation by technology cluster
The report’s approximately $47 million central indication is allocated among six principal technology clusters:
- Core bioelectric protein-expression platform: approximately $13.5 million
- Klotho modulation and Klotho-expressing stem-cell platform: approximately $12.5 million
- Brain and neuroregeneration technologies: approximately $6 million
- Tissue and organ-regeneration technologies: approximately $
6.5 million - Cancer-related bioelectric technologies: approximately $
3.5 million - Schuler-origin neurocode and closed-loop bioelectronic rights: approximately $4.5 million, subject to verification of ownership, assignment, exclusivity and remaining patent life
The central indication was reconciled using recognized intellectual-property valuation approaches, including replacement cost, relief from royalty, market and scorecard comparisons, risk-adjusted cash flow and real-option analysis for earlier-stage cell-therapy technologies.
The report specifically cautions that patent publications, continuations and issued grants should not simply be added together by count. Multiple publications may represent a single economic patent family, while one broad and commercially important patent family may be more valuable than numerous narrow applications.
Recent provisional patent applications and announced filings
The following new provisional patent applications or application initiatives have been identified in recent Lionheart Longevity news releases as additions or potential additions to the broader innovation portfolio:
- CerebraCell™ Multi-Protein Bioelectric Brain Regeneration Platform
A broad platform integrating programmable bioelectric expression of more than 60 regenerative proteins with Klotho-expressing stem cells in nutrient hydrogel, bioelectric-enhanced exosomes, peptides and other regenerative components.- DentaCell™ AI-Guided Bioelectric Regenerative Dentistry System
A personalized regenerative-dentistry platform combining artificial intelligence, diagnostics, programmable bioelectric stimulation and regenerative biologic approaches.- Bioelectric Expression of Thymulin
A multi-application platform involving Leonhardt Ventures, Lionheart Health and CancerCell focused on thymic function, immune regulation, healthy aging, regenerative medicine and potential cancer-related applications.- Bioelectric Controlled Expression of OSER1
A platform directed toward regulation of OSER1-associated healthspan, cellular resilience, stress-response and longevity pathways.- Bioelectric Stimulation of Bone to Increase Osteocalcin Expression
Technology intended to increase osteocalcin expression for potential brain, sexual, metabolic, musculoskeletal and healthy-aging benefits.- Bioelectric Enhancement of Menin Expression in the Brain
Technology licensed for development through the Brain Band™ platform and intended to support brain health, neuroregeneration, cognition and healthy aging.- Bioelectric Activation and Control of Wnt Signaling
An application directed toward hair regeneration, hearing restoration, joint health, tissue repair and longevity-related uses.- Bioelectric Expression of HMGB1
Technology designed to regulate HMGB1 for regeneration, stem-cell homing, tissue repair and longevity applications.- Bioelectric Modulation of FOXO3, AMPK and mTOR Pathways
A platform focused on major cellular pathways associated with metabolism, autophagy, cellular stress resistance, regeneration and healthspan longevity.- Bioelectric Activation of 15-PGDH
An application directed toward osteoarthritis, inflammatory diseases, tissue repair and regenerative-medicine applications.Recent news releases also describe the RegenaLung™ Klotho-Expressing Stem Cell Inhaler, combining Klotho-expressing regenerative cells with bioelectric activation for investigational lung repair and functional recovery. The valuation report assigns Klotho-expressing cell technologies risk-adjusted option value pending verification of patent schedules, assignments, prosecution status, regulatory rights and freedom to operate.
Two recently announced orthodontic provisional applications—IL-1β/PGE2 modulation for accelerated tooth movement and the ArchStim™ Smart Expansion and Stabilization System—are not included in this valuation because the report expressly excludes intellectual property owned by or attributable to OrthodontiCell.
Platform breadth and commercial potential
The included portfolio encompasses issued and pending patent families related to bioelectric control or modulation of Klotho, BDNF, GDF10, follistatin, Sestrin, Sirtuin proteins, NANOG, COL17A1, Sonic Hedgehog, inflammation, blood-pressure regulation, kidney treatment, skin and hair regeneration, tumor therapy and other regenerative pathways.
According to the report, the portfolio may support multiple commercialization models:
- Non-exclusive indication or geographic licenses
- Exclusive field-of-use licenses
- Research collaborations with downstream licensing options
- Device, software and therapeutic-program licensing
- Strategic combinations with stem cells, exosomes, peptides, hydrogels and diagnostics
- A potential portfolio sale or broader strategic transaction following comprehensive diligence
The report presents indicative licensing guideposts ranging from 4% to 7% royalties for non-exclusive field licenses and 6% to 10% royalties for exclusive field licenses, potentially accompanied by upfront fees, research funding, development milestones, minimum royalties and performance requirements. These figures are analytical negotiation guideposts and not firm offers or market quotations.
Scope and important limitations
The valuation covers applicable rights held by Lionheart Health and Leonhardt Ventures in bioelectric stimulators, programmed signaling protocols, controlled protein expression, regeneration systems, Klotho modulation, Klotho-expressing stem-cell combinations and qualifying Schuler-origin neuro-electrical technologies.
The analysis expressly excludes:
- Circulatory-assist pumps, pulsatile stent grafts and related intellectual property owned by or attributable to Second Heart Assist
- Orthodontic-treatment, dental-mouthpiece and related intellectual property owned by or attributable to OrthodontiCell
- Legacy inventions assigned to unrelated third parties unless a current enforceable license or reversion can be documented
The approximately $47 million central indication represents an analytical estimate of the included intellectual property—not a valuation of Lionheart Health or Leonhardt Ventures as operating companies. It does not separately value cash, commercial devices, regulatory clearances, clinical operations, contracts, manufacturing relationships, workforce, brands or goodwill.
The report is not a USPAP appraisal, audit opinion, fairness opinion, legal title opinion or investment recommendation. Patent ownership, enforceability, remaining life, freedom to operate, regulatory rights, clinical data and projected cash flows require further legal, technical and financial diligence before the valuation is used in a financing, tax, financial-reporting or binding transaction.
About Lionheart Health
Lionheart Health, Inc. is developing and commercializing a multi-modality platform combining bioelectric stimulation, regenerative biologics, Klotho-related technologies, cellular therapies, peptides, exosomes, diagnostics and lifestyle interventions to improve healthspan and address age-related decline. Its development portfolio includes the Lionheart 240 Stimulus™, BodStim™, Brain Band™, HairCell™, EyeCell™, OrthoStim™, CerebraCell™, MitoCell™ and Lionheart Octopus™ platforms.
About Leonhardt Ventures
Leonhardt Ventures LLC, founded in 1982, is an innovation and venture-development organization focused on organ regeneration, recovery, bioelectric medicine, longevity and related medical technologies. Its portfolio companies and licensees are developing technologies across cardiovascular, neurological, musculoskeletal, renal, pulmonary, skin, hair, dental and healthy-aging applications.
Media and partnership inquiries:
Lionheart Health, Inc.
Huntington Beach, California
www.LionheartLongevity.comSources: The 2026 IP Valuation Report and Lionheart Longevity’s recent news-release archive.
Forward-Looking Statement
This release contains forward-looking statements regarding intellectual-property value, licensing opportunities, research programs, clinical development, regulatory progress and commercialization potential. Actual results may differ materially because of scientific, clinical, regulatory, intellectual-property, financing, manufacturing and market risks. Provisional patent applications do not guarantee that patents will issue, that issued claims will provide commercially meaningful coverage or that any product or therapy will receive regulatory authorization.Howard J. LeonhardtExecutive Chairman & CEOLionheart Health, Inc.Leonhardt Ventures LLC4440 Von Karman, Ste 100Newport Beach, CA 92660
Lionheart Health and Leonhardt Ventures Announce Indicative $47 Million Central Valuation of Regenerative-Medicine IP Portfolio
Analytical report estimates a $24 million to $86 million fair-market-value range and a conditional $70 million to $185 million strategic-value…
